Apeiron Investment Group withdrew its nomination at Sensei Biotherapeutics
Key Summary: On November 2022, Apeiron Investment Group (11–14.5%) called for urgent action at the company, including possible liquidation, citing strategic missteps and value destruction. On March 9, 2023, it nominated three directors but later withdrew its slate after the company agreed to repurchase its shares at $1.58 each.
This post is for paying subscribers only
Subscribe to continue reading